Account Info
Log Out
English
Back
Log in to access Online Inquiry
Back to the Top

$Cardiol Therapeutics (CRDL.US)$ NEWS Cardiol Therapeutics A...

NEWS
Cardiol Therapeutics Announces Phase II ARCHER Trial Presented at the World Congress on Acute Heart Failure 2024
Cardiol Therapeutics presented its Phase II ARCHER trial at the World Congress on Acute Heart Failure 2024. The trial is evaluating CardiolRx™ in patients with acute myocarditis. The presentation included the trial design, rationale, and baseline data on the first 50 patients randomized. The ARCHER trial has exceeded 85% of target enrollment, with a target of 100 patients across multiple countries. Its primary measures are cardiac MRI assessments of left ventricular function and myocardial edema/fibrosis. The MAvERIC-Pilot Phase II study for recurrent pericarditis is expected to report topline results in June 2024. Acute myocarditis is a severe inflammatory condition with significant health risks. Cardiol's CEO highlighted the growing interest in myocarditis treatments and the contributions of clinical collaborators to the study's progress.
Positive
ARCHER trial exceeded 85% patient enrollment.
Presentation at a prestigious global event enhances visibility.
Acceptance for publication in the ESC Heart Failure journal.
Initial baseline values consistent with expected demographics.
MAvERIC-Pilot Phase II study results due in June 2024.
Global participation from renowned cardiovascular centers.
Growing interest and commitment from clinical collaborators.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
1
+0
1
Translate
Report
3144 Views
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1070Followers
68Following
7362Visitors
Follow